Lv0
0 积分 2024-07-05 加入
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial
1个月前
已完结
SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes
1个月前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
1个月前
已完结
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
1个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Impact of Firms’ Digital Technology Innovation on Export Product Quality Upgrading
5个月前
已完结
皖公网安备34019202002308
